Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial - Prince, H. Miles; Kim, Youn H.; Horwitz, Steven M.; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A.; Ortiz-Romero, Pablo L.; Akilov, Oleg E.; Geskin, Larisa; et al. (Lancet, 2017)